Abstract
17-Hydroxy-6α-methylprogesterone acetate (Provera), an active progestational agent, was used as systemic therapy for palliation of metastatic mammary carcinoma in 17 patients with osseous involvement. Hypercalcemia in 4 of these 17 patients was observed during treatment. The mechanism of the induction of the hypercalcemia was felt to result from a direct effect of the steroid (acting as a progestin) on breast cancer rather than through conversion to androgenic or estrogenic substances. Since hypercalcemia in mammary carcinoma usually reflects exacerbation of the disease, caution is advised in the use of active progestins in women with mammary carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
